-
Mashup Score: 4Pulmonary fibrosis - Symptoms and causes - 2 year(s) ago
Pulmonary fibrosis — Learn about the symptoms, causes and treatment of this serious lung disease that occurs when lung tissue becomes damaged and scarred.
Source: Mayo ClinicCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 6
Rationale: Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal disorder. Two FDA-approved anti-fibrotic drugs, nintedanib, and pirfenidone, slow the rate of decline in lu…
Source: www.atsjournals.orgCategories: General Medicine News, Latest HeadlinesTweet-
Following computational predictions, scientists demonstrate that cancer drug counters #pulmonaryfibrosis @yale https://t.co/OguyxEuvjT https://t.co/hmNQ5ckbAj
-
-
Mashup Score: 0Environmental exposures common in people with pulmonary fibrosis - 2 year(s) ago
Among individuals with familial pulmonary fibrosis, environmental exposures are common, vary by sex and influence the CT pattern, timing of disease onset and mortality, researchers reported. “Despite a linkage between exposures and specific interstitial lung disease diagnoses, remarkably little objective data exists as to the relationship between exposures and disease morphology or survival
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet-
Environmental exposures are common in patients with familial #pulmonaryfibrosis and vary by sex and influence disease outcomes, according to findings published in @AnnalsATS @VUMC_MD https://t.co/qguA6o3NQ5
-
-
Mashup Score: 2Registry Launched to Reach More Patients With PF - 2 year(s) ago
The Pulmonary Fibrosis Foundation launches a new initiative to capture more diverse patients with PF than the current registry allows.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
The @PFFORG has launched a new initiative in which they hope to capture a far more diverse representation of patients with #pulmonaryfibrosis than the current registry allows them to do, a press release from the PFF indicated. https://t.co/WSb4pzYVaW
-
-
Mashup Score: 8
This JAMA Insights Clinical Update discusses the diagnosis, prognosis, and treatment of combined pulmonary fibrosis and emphysema, which is likely underestimated and underreported.
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
JAMA Insights Clinical Update discusses the diagnosis, prognosis, and treatment of combined #pulmonaryfibrosis and #emphysema, which is likely underestimated and underreported. https://t.co/MdnYv0czPy
-
-
Mashup Score: 5Bridging Specialties™: Timely Diagnosis for ILD Patients | CHEST Pulse Podcast - American College of Chest Physicians - 2 year(s) ago
In this podcast episode, a family medicine physician and a pulmonologist discuss obstacles to reaching a definitive diagnosis for idiopathic pulmonary fibrosis and how we can overcome them.
Categories: Latest Headlines, PulmonologyTweet-
In the latest CHEST podcast, pulmonologist Dr. Andrew Limper and family physician Dr. Timothy Hernandez speak with CHEST President, Dr. @DavidSchulman, about shortening the time to diagnosis for ILDs like #PulmonaryFibrosis. Listen now: https://t.co/WoydfrzuSz #PF #IPF #MedEd https://t.co/symZamixUI
-
-
Mashup Score: 2
AstraZeneca and BenevolentAI have notched another achievement in their artificial-intelligence-powered drug discovery collaboration. | After securing targets in chronic kidney disease and idiopathic pulmonary fibrosis (IPF), AstraZeneca is collecting a second IPF target from its recently reupped collaboration with BenevolentAI.
Source: Fierce BiotechCategories: Healthcare Professionals, Latest HeadlinesTweet-
.@AstraZeneca collects 2nd #pulmonaryfibrosis target from @benevolent_ai #AI #drugdiscovery collaboration https://t.co/lwvscUn5TM
-
-
Mashup Score: 0
What characterizes the progressive fibrosing ILD phenotype, and what baseline factors associated with this phenotype may help guide clinical decision making?
Source: Pulmonology AdvisorCategories: Latest Headlines, PulmonologyTweet-
A study found that progression of fibrotic interstitial lung disease occurs in approximately 50% of patients at 24 months.. @ERSpublications #pulmonology #pulmonaryfibrosis @KerriBerriKerri @jolenehfisher @shapps999 @TeresaTo8 @Mo_Safavi @AndrewHalayko https://t.co/JeoAqXiwAk https://t.co/BtIi0pZDF0
-
-
Mashup Score: 1
Using nanoparticles coated in mannose, a type of sugar, scientists at the University of Illinois, Chicago (UIC), have developed a treatment for pulmonary fibrosis. Their findings in animal models hold promise for potentially treating the disease.
Categories: Future of Medicine, Latest HeadlinesTweet-
Using nanoparticles coated in mannose, a type of sugar, scientists at @thisisUIC have developed a potential treatment for #pulmonaryfibrosis. Their findings in animal models hold promise for potentially treating the disease. Read more:https://t.co/JzrUV7qSo8 https://t.co/a25RM5lNOi
-
-
Mashup Score: 6
Using nanoparticles coated in mannose, a type of sugar, scientists at the University of Illinois, Chicago (UIC), have developed a treatment for pulmonary fibrosis. Their findings in animal models hold promise for potentially treating the disease.
Categories: Future of Medicine, Latest HeadlinesTweet-
Using nanoparticles coated in mannose, a type of sugar, scientists at @thisisUIC have developed a potential treatment for #pulmonaryfibrosis. Their findings in animal models hold promise for potentially treating the disease. Read more:https://t.co/JzrUV7qSo8 https://t.co/yNZn2WPOYr
-
#Pulmonaryfibrosis is a lung disease that occurs when lung tissue becomes damaged and scarred. If medications and therapies don't help, a #LungTransplant may be appropriate. Learn more. https://t.co/zj1LgLjmXj #MayoClinic https://t.co/7PD44F2XEp